An interventional study of transcranial direct stimulation and Sham treatment in Migraine, sponsored by Istanbul Medipol University Hospital. Active, not recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Istanbul Medipol University Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 92 studies in Migraine Disorders with a site in Turkey — 20 open to participants now, 25 under way, 3 of them phase 3. Migraine Disorders · Turkey.
Among the 92 studies in Migraine Disorders with a site in Turkey, this one is the 32nd largest by planned enrollment of the 69 interventional ones that give a count, is one of 14 that started in 2024, is one of 56 with no phase, reaches primary completion later than 18 of the 24 other live ones, and was the 54th registered.
1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →20 of the 92 studies in Migraine Disorders with a site in Turkey are open now. Recruiting first, the newest first:
Ankara Yildirim Beyazıt University · Sites in Turkey
Ages 18–55
Bozok University · Sites in Turkey
Ages 18–65
Ankara Yildirim Beyazıt University · Sites in Turkey
Ages 18–55 · Healthy volunteers
Mustafa Kemal University · Sites in Turkey
Ages 18–55
Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey · Sites in Turkey
Ages 18–65 · Women only
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
92 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 14 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is close to the median of 80 across 1,271 interventional studies indexed under Migraine Disorders.
Median enrollment 73 across the 69 interventional studies, 130 across the 23 observational. Of the 63 that completed or were terminated, 5 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 92 have an industry lead sponsor. The 10 most frequent:
Istanbul Medipol University Hospital is the lead sponsor of 368 studies on the registry; 48 are open to participants now.
Istanbul Medipol University Hospital has 1 study filed under Migraine Disorders — fewer than ten, so there is no comparison to draw.
5 of the studies in Migraine Disorders with a site in Turkey that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04965675Phase 3H. Lundbeck A/SA Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine | 2027-03-26 |
| NCT05897320Phase 3H. Lundbeck A/SA Study of Eptinezumab in Pediatric Participants With Episodic Migraine | 2027-07-06 |
| NCT06468189Istanbul Medipol University HospitalClinical and Neurophysiological Effects of tDCS to Visual and Motor Cortex in Migraine | 2026-11 |
| NCT07261384Hacettepe University"Personalized Physiotherapy for Migraine: Effects on Pain, Fatigue, and Physical Function" | 2027-01-30 |
| NCT07657377Ankara Yildirim Beyazıt UniversityThe Effects of Physiotherapy in Migraine | 2027-08 |
Add all 5 to your calendar (.ics) → With an account.
Among the 92 studies in Migraine Disorders with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
tDCS can be offered as an alternative to migraine patients who have frequent and severe attacks and who are resistant to or unresponsive to preventive drug therapy. Additionally, this technique may also be an option for patients who refuse or have contraindications to taking anti-migraine medications. A decrease in headache severity and frequency is expected with this neuromodulation applied to migraine patients with frequent attacks. Based on this hypothesis; This tested whether simultaneous modulation of motor (M1, left) and visual cortex (O1 or O2, ipsilateral) with tDCS applied for 3 consecutive days is an effective treatment for migraine patients for the following specific purposes . No significant undesirable effects are expected, except for possible side effects that are simple and do not require medical intervention, such as tingling or itching in the area where the electrodes are attached, moderate fatigue, mild headache, nausea at a rate of less than 3%, and insomnia at a rate of less than 1%. . The research will be conducted within the framework of ethical principles and in accordance with the good clinical practice protocol.
A) The primary purpose of this study is to determine whether transcranial direct current stimulation applied simultaneously to the motor and visual cortex in migraine patients provides a significant reduction in pain due to migraine attacks compared to sham tDCS. Additionally, to evaluate the effects of this treatment, They will be measured changes in the number of migraine attacks, abortive medication intake (e.g., opioids, triptans), as well as overall improvement in cognitive status and quality of life. In addition, electrophysiological EEG evaluations, before and after treatment, and the results of these measurements, as a potential biomarker in migraine, will be compared in the active and sham groups.
B) It is aimed to determine whether the clinical effects of tDCS are long-lasting. Therefore, It will compared whether there is a difference in improvement of migraine-related pain between active and sham tDCS at pre-treatment (baseline) assessments as well as at 1, 2, and 3 months after treatment.
C) Finally, it will be examined whether tDCS treatment applied for 3 consecutive days in migraine patients is safe. Safety will be evaluated through neuropsychological testing and adverse event reporting.
Headache disorders are quite common. In the 2016 Global Burden of Disease Study, migraine was the second highest cause of disability overall and the most common disease causing disability in young adults (15-49 years). When there are frequent or severe migraine attacks, pharmacological agents are used to reduce the frequency of migraine attacks. Standard migraine prophylactic treatments show either low efficacy or undesirable side effects, and most of them are licensed for other diseases and not for migraine. Additionally, some migraine patients are hesitant to choose pharmacological treatment. Compliance with these treatments is also quite low in the medication-using group. Recently used calcitonin gene-related peptide (CGRP) monoclonal antibody treatments are quite expensive treatments. Therefore, there remains a need for an effective, tolerable and affordable prophylactic treatment for migraine.
Migraine is complex, involving several circuits of both the central and peripheral nervous system and has a still unclear pathophysiology. Trigeminovascular activation is the key event of migraine pain, mostly related to the peripheral nervous system, but the central nervous system also plays a role in the formation and perception of migraine. The cerebral cortex of migraineurs is hypersensitive (overexcitable) to external stimuli, possibly due to altered functional connectivity in subcortical structures, including the thalamus. This resulting "thalamo-cortical dysrhythmia" and changes in excitability can be controlled with non-invasive neuromodulation techniques such as transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS).
Non-invasive neuromodulation is applied to various forms of primary headaches and is recommended as an easily applicable method for both episodic and chronic migraine. So far, only single pulse transcranial magnetic stimulation (sTMS), vagus nerve stimulation (VNS), and supraorbital neurostimulation have been approved by the FDA for the treatment of migraine. Transcranial direct current stimulation (tDCS; direct current stimulation) is an electrical stimulation method used for non-invasive brain stimulation, where a weak electrical current of approximately 2 milliamps is applied through two scalp electrodes with a portable battery-powered system. tDCS is an electrical stimulation technique in which low-amplitude direct current is applied to the skull via surface electrodes, thereby modulating neural brain activity. The applied current changes the transmembrane neuronal potential and thus affects the level of excitability. Depending on the polarity of the active electrodes, tDCS can increase or decrease cortical excitability. tDCS has been shown to trigger changes in neuropsychological and motor activity in the brain. Protocols with variable session numbers (1-20 days) applied to different targeted brain regions provide promising results in pain syndromes by regulating pain-related pathways in various ways. Stimulation of the motor cortex with tDCS has already been shown to relieve pain in patients with traumatic spinal cord injury and other chronic pain syndromes, including fibromyalgia. Migraine patients are often hypersensitive to pain. A treatment that targets areas of the brain involved in the experience of pain may also help reduce pain in migraine patients. According to the results of systematic review and meta-analysis of studies conducted so far; tDCS has been evaluated as an effective, reliable method that can improve migraine symptoms by activating the motor cortex or activating/inhibiting the visual cortex. Additionally, tDCS treatment repeated for days over a period of 4 weeks or longer is effective in reducing migraine pain severity and attack duration. The benefit of tDCS may persist for at least 4 weeks after completion of the last tDCS session. Both anodal and cathodal stimulation have been evaluated as effective for reducing migraine pain severity. The study protocol present here aims to test a unique protocol with simultaneous anodal stimulation to the motor area and cathodal stimulation to the visual cortex. In the meta-analyses conducted so far; In future clinical studies using tDCS in migraine, the importance of simultaneously measuring neuronal activity using EEG or fMRI(Functional magnetic resonance imaging)( is also emphasized in order to better understand the underlying mechanisms of action. Electrophysiological techniques, such as quantitative electroencephalography (qEEG), provide important information about brain functioning at rest and during sensory stimulation. A large amount of data has demonstrated the presence of some excitability changes in the occipital cortex during the interictal period of migraine patients.While some studies have demonstrated hyperexcitability, only a few studies have been able to document a decrease in occipital excitability. This increase in occipital excitability has recently been recognized as an inhibition phenomenon, and a new term "hyperresponsiveness" in migraine has come into use in the last decade. This hyperexcitability has been demonstrated in many neurophysiological and neuroimaging studies as loss of habituation to recurrent stimuli. Clearly, spectral analysis of different frequency bands of qEEG helps us understand the intrinsic activity of the migraineur brain. Differences in peak latency, amplitude, and synchronization of EEG frequency bands in response to sensory stimulation have been reported in migraine patients compared with healthy subjects. In this study, it is planned to make comparative evaluations in the following months with EEG recordings to be taken before and after simultaneous motor cortex and visual cortex stimulation. In this way, the relationship between anodal and cathodal transcranial direct current stimulation and different frequency bands in the occipital region will be determined by comparing the active treatment and sham groups.
Review studies and recent studies from our country have shown that tDCS treatment is an effective and safe prophylactic treatment in migraine patients with allodynia in both short and long-term follow-ups. In order to obtain better clinical evidence in this field, as emphasized in the Cochrane analysis conducted in 2018; Randomized controlled studies with larger samples and clinically meaningful long-term results are needed. In these studies, it is planned to test the clinical effect of a protocol combination, which has been shown to be particularly effective, in prophylaxis in migraine patients in a large sample group, while also evaluating its neurophysiological responses in active and sham groups.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
tDCS Interictal application will be performed during the attack-free period. Experimental group, 3 consecutive sessions, cathodal to occipital cortex (O1 or O2, ipsilateral); anodal to M1 (left)
Device: transcranial direct stimulation
Control group, 3 consecutive sessions of sham stimulation to the same locations.
Device: Sham treatment
Mars-01(Marslab, Turkey) transcranial direct current stimulation device works with a 9 volt battery and consists of two 5x5 (25 cm2) electrodes (anode and cathode). 3 consecutive sessions (days), cathodal to occipital cortex (O1 or O2, ipsilateral); Anodal application will be made to M1 (left). Active stimulation is 2mA tDCS with a 0 to 30 second acceleration period of 20 minutes per session. Placebo stimulation will be applied according to the device's own sham software protocol. Accordingly, the current consists of 30 seconds of increase from 0 to 2mA(milliamp), 10 seconds of stimulation, 30 seconds of decrease to 0 and 20 minutes of current-free application.
The same device used for stimulation will be used, but no stimulation will be given.
Change in headache diary variables
The number of migraine attacks, pain intensity, duration of each attack and the number of painkillers taken will be evaluated. Patients will answer this diary throughout the entire experimental period (months).
Time frame: Baseline (Before Treatment) / 1 month and 3 months after treatment
EEG Power Spectrum Analysis
10 minutes of resting-state EEG recording.EEG data will be separated into one-second epochs after they are cleared of noise. Power spectrums of these data will be obtained in the delta, theta, alpha, beta and gamma frequency bands. Each epoch will be analyzed by Fast Fourier Transform (FFT, Fast Fourier Transform) with 10% Hanning window, then power spectrum analysis will be performed, giving the frequency values for each electrode by averaging all FFTs. Maximum peaks will be determined in the delta (0.5-3.5 Hz), theta (4-7 Hz), alpha (8-13 Hz), beta (15-28 Hz) and gamma (28-48 Hz) frequency bands. these values will be used in statistical analysis for each person and electrode.
Time frame: Baseline (Before Treatment) / 1 month and 3 months after treatment
EEG Coherence Analysis
Coherence measurements at delta, theta, alpha, beta and gamma frequencies can be analyzed for either intra-hemispheric electrode connections or inter-hemispheric electrode connections.Coherence values take values between 0-1. Values close to 0 indicate that there is no connection at the determined frequency between the two calculated electrode regions, while values close to 1 indicate a high coupling between the two electrode regions.Coherence values will be calculated with the Brain Vision Analyzer program using the formula below.The data obtained during memory and visualization will be separated into one-second epochs after they are cleared of noise.Power spectrums of these data will be obtained in the delta, theta, alpha, beta and gamma frequency bands. Each epoch will be analyzed by Fast Fourier Transform with 10% Hanning window.Then, these data will be calculated for all possible electrode pairs using the brain vision analysis program with the formula given below.
Time frame: Baseline (Before Treatment) / 1 month and 3 months after treatment
EEG functional connectivity analysis
10 minutes of resting-state EEG recording. eLORETA software will be used for functional connectivity analysis. sLORETA /eLORETA is an online free software developed by Roberto Pascual-Marqui and his team (http://www.uzh.ch/keyinst/loreta.htm). eLORETA is an algorithm developed to solve the inverse problem and it does not contain localization bias even in the presence of noise . In this software, resting state data with eyes closed, separated into 2 second epochs, whose artifacts are cleaned by preprocessing, will be used. The relevant areas to be analyzed in the cortical plane and the relevant frequency band gaps will be determined. The time series containing the eLORETA current source density obtained from these areas will be calculated and a "lagged linear coherence" matrix will be created to be applied in graph theory (Vecchio et al., 2014). "Lagged linear coherence" will give correct physiological connectivity unaffected by volume conduction and low spatial resolution.
Time frame: Baseline (Before Treatment) / 1 month and 3 months after treatment
Changes in the Headache Impact Scale (HIT-6)
Headache Impact Scale items evaluate vitality, pain, and psychological distress, as well as domains such as sociability, role, and cognitive functioning. Headache Impact Test (HIT-6) questionnaire was designed to helping describe and communicate the way people feel and what they cannot do because of headaches. Interpreting Headache Impact Test scores is achieve through a simple summary of the six items in the survey, ranging from 36 to 78 with larger scores reflecting greater impact. Levels of headache impact severity can be categorized using score ranges based on the HIT-6 interpretation guide into one of four areas: little or no impact (49 or less), some impact (50-55), substantial impact (56-59), and severe impact (60-78).
Time frame: Baseline (Before Treatment) / 1 month and 3 months after treatment
Changes in Visual Analogue Scale (VAS)
The Visual Analogue Scale (VAS) measures pain intensity. The VAS consists of a 10cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be'). Ask the patient to rate their current level of pain by placing a mark on the line. Use a ruler to measure the distance in centimetres from the 'no pain marker' (or zero) to the current pain mark. This provides a pain intensity score out of 10; for example, 6 out of 10 (or 6/10).
Time frame: Baseline (Before Treatment) / 1 month and 3 months after treatment
MoCA Tests Scores
The Montreal Cognitive Assessment (MoCA) was designed as a rapid screening instrument for mild cognitive dysfunction. It assesses different cognitive domains: attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. Time to administer the MoCA is approximately 10 minutes. The total possible score is 30 points; a score of 26 or above is considered normal.
Time frame: Baseline (Before Treatment) / 1 month and 3 months after treatment
Beck depression Tests Scores
The Beck Depression Inventory (BDI; Beck \& Steer, 1993) is a 21-item self-report instrument that generates one score reflecting the level of depression as being minimal, mild, moderate, or severe.
Time frame: Baseline (Before Treatment) / 1 month and 3 months after treatment
Anxiety scales
Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe.
Time frame: Baseline (Before Treatment) / 1 month and 3 months after treatment
tDCS side effect registration form
Any side effects occurring in the application area (during or after) Any general side effects that occur at the end of the application will be recorded.
Time frame: Baseline (Before Treatment) / 1 month and 3 months after treatment
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2024 (actual). Primary completion is estimated for Nov 2026, 32 months after the start.
Of 310 non-industry interventional studies with no phase under Migraine Disorders, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 32 months is above that.
Counting every sponsor, half of 360 studies reached it within 15 months; a quarter within 7 and three quarters within 33.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Nov 2025 → Nov 2026 and completion Nov 2025 → Nov 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Istanbul Medipol University Hospital →